Semaglutide vs AOD-9604

Overview

Semaglutide and AOD-9604 represent two vastly different philosophical approaches to metabolic research. Semaglutide is a pharmaceutical-grade GLP-1 receptor agonist backed by extensive clinical trial data and regulatory approval worldwide. AOD-9604 is a modified fragment of human growth hormone that showed initial promise in fat metabolism research but ultimately failed to achieve regulatory approval.

Comparing these two peptides is less about which is “better” and more about understanding the entirely different mechanisms, evidence bases, and regulatory landscapes that define each compound. For Canadian researchers, the distinction between an approved pharmaceutical and an unregulated research chemical is particularly relevant.

Quick Comparison Table

Mechanism of Action: Completely Different Targets

Semaglutide works by mimicking GLP-1 (glucagon-like peptide-1), an incretin hormone released by the gut after eating. It binds to GLP-1 receptors in the pancreas, gut, and brain. The pancreatic effects improve insulin secretion and suppress glucagon. The gut effects dramatically slow gastric emptying, making people feel full longer. The central nervous system effects directly reduce appetite through hypothalamic signalling. Semaglutide's 94% homology to native GLP-1, combined with structural modifications that resist DPP-4 degradation, give it a half-life of approximately 7 days — enabling once-weekly dosing.

AOD-9604 takes an entirely different approach. It is a synthetic analogue of the lipolytic (fat-burning) region of human growth hormone — specifically amino acids 177–191 with a tyrosine modification. The hypothesis behind AOD-9604 is that this fragment retains hGH's fat-metabolising properties without the diabetogenic, IGF-1-raising, or growth-promoting effects of full-length growth hormone. It is thought to work through the β3-adrenergic receptor pathway, stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat creation) in adipose tissue.

Evidence Base: A Stark Contrast

Semaglutide: Robust Clinical Evidence

Semaglutide is supported by one of the most comprehensive clinical trial programmes in metabolic medicine. The STEP trials (Semaglutide Treatment Effect in People with obesity) demonstrated:

• STEP 1: 16.9% mean body weight reduction over 68 weeks versus 2.4% for placebo
• STEP 2: 9.6% weight loss in patients with type 2 diabetes
• STEP 3: 16.0% with intensive behavioural therapy
• SELECT trial: 20% reduction in major cardiovascular events

The evidence is Phase III, randomised, double-blind, placebo-controlled, with thousands of participants and long follow-up periods. This is the gold standard of clinical evidence.

AOD-9604: Promising Theory, Disappointing Trials

AOD-9604's clinical evidence is far more limited. Early animal studies were promising — rodent models showed significant reductions in body fat without the metabolic side effects of full-length hGH. However, human trials told a different story:

• Phase IIb trial (2007): 536 participants over 24 weeks. The primary endpoint (body weight change) was not statistically significant versus placebo. Mean weight loss was approximately 2.8 kg in the treatment group versus 1.5 kg for placebo.
• Metabolic Pharmaceuticals Ltd. (the developer) subsequently ceased development for obesity
• AOD-9604 has since been explored for osteoarthritis and cartilage repair, but with limited published data

Safety Profiles

Semaglutide has well-documented side effects. Gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation) are the most common, affecting 40–70% of users initially but typically improving over time. More serious concerns include pancreatitis risk, gallbladder disease, and a black box warning for medullary thyroid carcinoma (based on rodent data). Reports of suicidal ideation are being investigated but not confirmed as causal.

AOD-9604 demonstrated a favourable safety profile in its clinical trials — side effects were mild and similar to placebo. This is one of the peptide's genuine advantages: it appears to be well-tolerated. However, long-term safety data is limited due to the abbreviated development programme. As with all research peptides, proper reconstitution and storage are essential for maintaining compound integrity.

Canadian Context

Semaglutide is available by prescription in Canada. Ozempic® (for type 2 diabetes) and Wegovy® (for weight management) are both Health Canada–approved. Supply shortages have been a significant issue since 2023, with periodic availability constraints. Provincial formulary coverage varies — some provinces cover Ozempic for diabetes but not Wegovy for weight management specifically.

AOD-9604 is available from Canadian research chemical suppliers without a prescription. It is not approved by Health Canada and is sold strictly as a research compound — see our legality guide for details. It has recently been classified by WADA as a banned substance (S0 category), which affects competitive athletes. Always verify product quality with a Certificate of Analysis.

Looking for how Semaglutide compares to the next generation of metabolic peptides? See our Semaglutide vs Retatrutide comparison, examining the approved GLP-1 single agonist against the investigational triple agonist.

Bottom Line for Researchers

• Studying GLP-1 pathway or appetite neuroscience? Semaglutide is the gold standard with extensive published data to build upon.
• Investigating hGH fragment lipolysis? AOD-9604 isolates the fat-metabolising region of growth hormone without confounding growth or diabetogenic effects.
• Comparing efficacy? The clinical evidence strongly favours semaglutide for meaningful weight reduction.
• Studying tolerability? AOD-9604's mild side effect profile makes it interesting for safety-focused research designs.